InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Lineage Cell Therapeutics, Inc.

LCTX Clue Score43
United States Fiscal year ends December CIK 0000876343
$0.99 -3.50% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $0.99 −58.76% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 12 Oct 2016. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Revenue5.9Operating income−59.0Net income33.6EPS, diluted0.34Fiscal year 2017Revenue3.5 −41.6%Operating income−38.9Net income−20.0 −159.5%EPS, diluted−0.17 −150.0%Fiscal year 2018Revenue5.0 +44.2%Operating income−41.8Net income−46.0Fiscal year 2019Revenue3.5 −29.5%Operating income−38.9Net income−11.7Fiscal year 2020Revenue1.8 −48.1%Operating income−26.4Net income−20.6Fiscal year 2021Revenue4.3 +137.7%Operating income−49.2Net income−43.0Fiscal year 2022Revenue14.7 +238.7%Operating income−22.5Net income−26.3EPS, diluted−0.15Fiscal year 2023Revenue8.9 −39.2%Operating income−24.7Net income−21.5EPS, diluted−0.12Fiscal year 2024Revenue9.5 +6.2%Operating income−21.5Net income−18.6EPS, diluted−0.09Fiscal year 2025Revenue14.6 +53.2%Operating income−36.6Net income−63.5EPS, diluted−0.28
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue 5.9 3.5 5.0 3.5 1.8 4.3 14.7 8.9 9.5 14.6
Growth −41.6% +44.2% −29.5% −48.1% +137.7% +238.7% −39.2% +6.2% +53.2%
Operating income −59.0 −38.9 −41.8 −38.9 −26.4 −49.2 −22.5 −24.7 −21.5 −36.6
Net income 33.6 −20.0 −46.0 −11.7 −20.6 −43.0 −26.3 −21.5 −18.6 −63.5
Growth −159.5%
EPS, diluted 0.34 −0.17 n/a n/a n/a n/a −0.15 −0.12 −0.09 −0.28
Growth −150.0%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2016Gross margin94.0%Operating margin−995.6%Net margin566.8%Free cash flow margin−752.6%Fiscal year 2017Gross margin95.1%Operating margin−1,125.0%Net margin−577.7%Free cash flow margin−920.9%Fiscal year 2018Gross margin93.9%Operating margin−837.9%Net margin−922.0%Free cash flow margin−630.3%Fiscal year 2019Gross margin88.3%Operating margin−1,106.0%Net margin−333.1%Free cash flow margin−921.4%Fiscal year 2020Gross margin78.9%Operating margin−1,448.4%Net margin−1,130.8%Free cash flow margin−1,085.3%Fiscal year 2021Gross margin67.2%Operating margin−1,133.6%Net margin−991.0%Free cash flow margin−550.6%Fiscal year 2022Gross margin95.0%Operating margin−153.2%Net margin−178.7%Free cash flow margin4.4%Fiscal year 2023Gross margin92.5%Operating margin−276.5%Net margin−240.2%Free cash flow margin−326.9%Fiscal year 2024Operating margin−226.1%Net margin−195.9%Free cash flow margin−249.0%Fiscal year 2025Operating margin−251.6%Net margin−436.5%Free cash flow margin−133.6%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Gross margin 94.0% 95.1% 93.9% 88.3% 78.9% 67.2% 95.0% 92.5% n/a n/a
Operating margin −995.6% −1,125.0% −837.9% −1,106.0% −1,448.4% −1,133.6% −153.2% −276.5% −226.1% −251.6%
Net margin 566.8% −577.7% −922.0% −333.1% −1,130.8% −991.0% −178.7% −240.2% −195.9% −436.5%
Free cash flow margin −752.6% −920.9% −630.3% −921.4% −1,085.3% −550.6% 4.4% −326.9% −249.0% −133.6%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−42.3Capital expenditure−2.2Free cash flow−44.6Fiscal year 2017Operating cash flow−30.5Capital expenditure−1.3Free cash flow−31.8Fiscal year 2018Operating cash flow−30.9Capital expenditure−0.6Free cash flow−31.4Fiscal year 2019Operating cash flow−31.9Capital expenditure−0.4Free cash flow−32.4Fiscal year 2020Operating cash flow−19.8Capital expenditure−0.1Free cash flow−19.8Fiscal year 2021Operating cash flow−23.6Capital expenditure−0.3Free cash flow−23.9Fiscal year 2022Operating cash flow1.1Capital expenditure−0.4Free cash flow0.6Fiscal year 2023Operating cash flow−28.6Capital expenditure−0.7Free cash flow−29.2 −4,626.3%Fiscal year 2024Operating cash flow−23.1Capital expenditure−0.6Free cash flow−23.7Fiscal year 2025Operating cash flow−18.9Capital expenditure−0.5Free cash flow−19.4
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −42.3 −30.5 −30.9 −31.9 −19.8 −23.6 1.1 −28.6 −23.1 −18.9
Capital expenditure −2.2 −1.3 −0.6 −0.4 −0.1 −0.3 −0.4 −0.7 −0.6 −0.5
Free cash flow −44.6 −31.8 −31.4 −32.4 −19.8 −23.9 0.6 −29.2 −23.7 −19.4
Growth −4,626.3%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash22.1Shareholders’ equity117.9Fiscal year 2017Cash36.8Shareholders’ equity162.6Fiscal year 2018Cash23.6Shareholders’ equity93.8Fiscal year 2019Cash9.5Shareholders’ equity113.0Fiscal year 2020Cash32.6Shareholders’ equity96.2Fiscal year 2021Cash55.7Shareholders’ equity92.2Fiscal year 2022Cash11.4Shareholders’ equity73.3Fiscal year 2023Cash35.4Shareholders’ equity63.4Fiscal year 2024Cash45.8Shareholders’ equity78.4Fiscal year 2025Cash40.8Shareholders’ equity44.5
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 22.1 36.8 23.6 9.5 32.6 55.7 11.4 35.4 45.8 40.8
Shareholders’ equity 117.9 162.6 93.8 113.0 96.2 92.2 73.3 63.4 78.4 44.5

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
5.9 3.5 5.0 3.5 1.8 4.3 14.7 8.9 9.5 14.6
Growth −41.6% +44.2% −29.5% −48.1% +137.7% +238.7% −39.2% +6.2% +53.2%
0.4 0.2 0.3 0.4 0.4 1.4 0.7 0.7 0.3 n/a
5.6 3.3 4.7 3.1 1.4 2.9 14.0 8.3 n/a n/a
Growth −40.9% +42.4% −33.8% −53.6% +102.3% +379.4% −40.8%
36.1 24.0 21.0 17.9 12.3 33.9 14.0 15.7 12.5 17.7
28.4 19.9 24.7 24.0 15.6 18.2 22.5 17.3 18.2 18.5
−59.0 −38.9 −41.8 −38.9 −26.4 −49.2 −22.5 −24.7 −21.5 −36.6
Growth
18.6 −23.3 −47.1 −19.2 −21.9 −43.3 −25.8 −23.3 −18.6 −68.6
n/a n/a 0.3 −7.4 −1.2 n/a 0.5 −1.8 0.0 −5.3
33.6 −20.0 −46.0 −11.7 −20.6 −43.0 −26.3 −21.5 −18.6 −63.5
Growth −159.5%
Per share
0.35 −0.17 n/a n/a n/a −0.26 −0.15 −0.12 −0.09 −0.28
0.34 −0.17 n/a n/a n/a n/a −0.15 −0.12 −0.09 −0.28
Growth −150.0%
97.3 114.5 n/a n/a n/a 164.5 169.8 172.7 200.2 230.1
99.6 114.5 n/a n/a n/a n/a 169.8 172.7 200.2 230.1
Growth +15.0% +1.7% +15.9% +14.9%

Five years in brief

Worked out from the figures above, not from a press release
  • Revenue grew 51.5% a year over five years.
  • The diluted share count rose 131.1% in five years, which is dilution.
  • Operating margin is up 1,196.8 points on five years ago, at -251.6%.
  • A net loss in 9 of 10 years on file.